Top Page
Chimeric Therapeutics Ltd.
(Sydney:CHM)
Chimeric Therapeutics Ltd. (CHM) vs. iShares MSCI Australia ETF (EWA)
Chimeric Therapeutics Ltd. Business Overview & Revenue Model
Chimeric Therapeutics Ltd. Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.80M | 7.46M | 4.51M | 2.62M | 2.65K | 0.00 | Gross Profit |
| 3.32M | 7.45M | 3.54M | 1.67M | -844.31K | 0.00 | EBIT |
| -14.17M | -12.31M | -29.49M | -13.82M | -15.11M | -64.01K | EBITDA |
| -14.50M | -11.30M | -24.02M | -13.62M | -14.00M | 0.00 | Net Income Common Stockholders |
| -17.83M | -12.53M | -25.92M | -14.62M | -15.11M | -64.01K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.63M | 3.05M | 5.37M | 18.38M | 22.41M | 100.00 | Total Assets |
| 22.52M | 15.27M | 22.38M | 34.88M | 36.50M | 100.00 | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 34.01K | Net Debt |
| -3.63M | -3.05M | -5.37M | -18.38M | -22.41M | 33.91K | Total Liabilities |
| 6.56M | 12.80M | 16.71M | 9.17M | 11.37M | 64.01K | Stockholders Equity |
| 15.95M | 2.47M | 5.66M | 25.71M | 25.13M | -63.91K |
| Cash Flow | Free Cash Flow | ||||
| 274.83K | 10.11K | -16.43M | -13.69M | -14.15M | -34.01K | Operating Cash Flow |
| -5.51M | -7.54M | -16.32M | -13.15M | -8.84M | -34.01K | Investing Cash Flow |
| 2.52K | 0.00 | -112.19K | -564.88K | -5.30M | 0.00 | Financing Cash Flow |
| 6.98M | 8.26M | 263.68K | 9.50M | 36.54M | 34.11K |
Chimeric Therapeutics Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$205.88M | ― | -37.20% | ― | ― | 32.02% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
42 Neutral | AU$10.08M | ― | -180.09% | ― | ― | 28.57% | |
41 Neutral | $119.47M | ― | -99.05% | ― | ― | -34.09% | |
36 Underperform | AU$3.32M | ― | -119.28% | ― | ― | 64.10% | |
30 Underperform | $738.77M | ― | ― | -24.46% | -7.90% |
Chimeric Therapeutics Ltd. Corporate Events
Chimeric Therapeutics Ltd announced a change in the substantial holding of its shares, with Paul Hopper’s voting power decreasing from 12.4% to 11.3%. This change was due to Deborah Coleman’s participation in an entitlement offer, which affected 10 million shares. The announcement highlights shifts in shareholder dynamics, potentially impacting the company’s governance and strategic decisions.
Chimeric Therapeutics Limited has announced a change in the director’s interest, with Paul Hopper acquiring an additional 10 million shares and 10 million options indirectly through participation in an entitlement offer. This change reflects a strategic move by the company to strengthen its financial position and potentially enhance its market presence, impacting stakeholders by increasing the director’s stake in the company.
Chimeric Therapeutics Limited announced a change in the director’s interest, with Phillip Hains acquiring an additional 2,608,696 ordinary shares and the same number of options through participation in an entitlement offer. This change reflects the company’s ongoing efforts to strengthen its financial position and enhance shareholder value, potentially impacting its market presence and stakeholder interests.
Chimeric Therapeutics Ltd. has announced the issuance of 197,203,052 securities under an Entitlement Offer, as per the prospectus dated March 18, 2025. This move is part of the company’s strategy to enhance its financial position and support its ongoing research and development efforts in the field of cancer therapeutics.
Chimeric Therapeutics has announced that the Emory Winship Cancer Institute in Atlanta, Georgia, has joined its Phase 1/2 clinical trial for CHM CDH17, a novel CAR-T cell therapy targeting CDH17, a biomarker linked to poor prognosis in gastrointestinal tumors. This milestone marks the opening of the fourth and final clinical trial site in the USA, demonstrating Chimeric’s commitment to advancing cell therapy and enhancing its value to patients and shareholders.
Chimeric Therapeutics has completed its entitlement offer, raising approximately $1 million through the issuance of new shares and options, though a shortfall of $2.2 million remains. The funds will support the company’s ongoing cell therapy programs, with trading of the new shares and options set to commence on 1 May 2025. The entitlement offer reflects continued shareholder support and positions Chimeric to further its innovative cancer treatment initiatives.
Chimeric Therapeutics announced significant progress in its clinical trials for the quarter ending March 31, 2025. The CHM CORE-NK studies have advanced with patient recruitment and dosing at prominent U.S. cancer centers, while the CHM CDH17 CAR-T trial, targeting advanced cancers, has expanded to include the University of Chicago Medicine. This trial is notable for its pioneering approach as the first anti-CDH17-directed CAR-T therapy, showing promising preclinical results. The company also secured $4 million in non-dilutive funding to support these developments, indicating strong financial backing and potential for impactful advancements in cancer treatment.
Chimeric Therapeutics Ltd. has announced that its previously unlisted options, issued under the ASX code CHMAAC, are now listed on the ASX under the code CHMO. This move allows option holders to trade these options on the ASX, aligning with the company’s recent non-renounceable pro-rata entitlement offer. The listing does not change the number or terms of the options, and the entitlement offer is set to close on 22 April 2025. This development is expected to enhance the liquidity and accessibility of the company’s options, potentially benefiting stakeholders by increasing market engagement and investment opportunities.
Chimeric Therapeutics Limited has announced an extension of the closing date for its non-renounceable entitlement offer to 22 April 2025. This extension provides shareholders with additional time to participate in the offer, potentially impacting the company’s capital structure and shareholder base. The offer includes the opportunity for eligible shareholders to apply for additional shares under a Top Up Facility, which could enhance shareholder value and support the company’s ongoing development of its cell therapy portfolio.
Chimeric Therapeutics Ltd. has released an analysis of its holdings, revealing that 157 holders collectively own 624,999,999 units, representing 100% of the company’s shares. The largest shareholder, Deborah Anne Coleman, holds 12.8% of the total securities. This distribution of holdings reflects the company’s shareholder structure and could influence future strategic decisions and investor relations.
Chimeric Therapeutics Ltd. has announced the quotation of a new class of options on the Australian Securities Exchange (ASX), with 624,999,999 options expiring on December 19, 2025, at an exercise price of $0.008. This move is expected to enhance the company’s capital structure, potentially providing additional funding for its ongoing research and development efforts in the field of cancer immunotherapy, thereby strengthening its position in the biotechnology sector.
Chimeric Therapeutics has announced the opening of its Entitlement Offer, which aims to raise approximately $3.2 million. This offer, which includes a non-renounceable pro rata entitlement of new shares and options, is expected to impact the company’s financial standing and market positioning positively.
Chimeric Therapeutics Ltd. has announced a proposed issue of 25 million securities, which are options expiring on various dates and at various prices, set to be issued on April 15, 2025. This strategic move is likely to bolster the company’s financial position, potentially enhancing its capacity to further develop its CAR-T therapies and strengthen its market presence in the biotechnology sector.
Chimeric Therapeutics Ltd. announced an update to its proposed issue of securities, noting that security holder approval is not required for the issuance of options. The update includes a revised timetable and a minor adjustment to the number of shares and options to be issued, reflecting changes in the shares on issue. This development may streamline the company’s capital raising efforts and potentially enhance its financial flexibility, impacting its strategic positioning in the biotechnology sector.
Chimeric Therapeutics Ltd. has announced a non-renounceable pro rata entitlement offer to raise approximately $3.2 million through the issuance of new shares and options. The offer includes 2 new shares for every 5 existing shares and 1 new option for each new share issued. Additionally, up to 25 million adviser options will be issued to PAC Partners Securities Pty Ltd and Taylor Collison Limited as joint lead managers. This move is aimed at strengthening the company’s financial position and is considered speculative, indicating potential risks for investors.
Chimeric Therapeutics Limited has announced a non-renounceable entitlement offer to raise approximately $3.2 million. The funds will primarily support the development of their CHM CDH17 Phase 1/2 clinical trial and the CORE-NK program. The offer includes new shares and options at a discounted price, with the proceeds also aiding general working capital and costs associated with the capital raising. This move is expected to enhance Chimeric’s operational capabilities and strengthen its position in the biotechnology sector.
Chimeric Therapeutics Ltd. announced the issuance of 25 million fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) as of March 17, 2025. This move is part of previously announced transactions and is expected to enhance the company’s capital base, potentially supporting its ongoing research and development efforts in the field of cancer therapeutics.
Chimeric Therapeutics announced its participation in the NWR Virtual Healthcare Conference, where CEO Dr. Rebecca McQualter will present. This engagement highlights Chimeric’s ongoing efforts to promote its pioneering cell therapy programs, which include advanced clinical trials for their CAR-T and NK cell therapies, potentially enhancing their market presence and stakeholder interest.
Chimeric Therapeutics Ltd. announced the lifting of its trading suspension on the ASX following its decision to conduct an entitlement offer after a previously planned capital raising was not undertaken. This move is expected to impact the company’s financial strategy and market positioning, potentially influencing investor confidence and stakeholder engagement.
Chimeric Therapeutics Limited announced a proposed issue of securities, involving a standard pro rata issue of 638,059,938 options and ordinary shares. This move is expected to enhance the company’s capital structure, potentially impacting its market position and providing additional resources for its ongoing research and development efforts.
Chimeric Therapeutics has announced an Entitlement Offer to raise approximately $3.2 million, primarily to support the development of its CHM CDH17 Phase 1/2 clinical trial. The offer allows eligible shareholders to purchase new shares at a discounted price, with additional options available, aiding the company’s ongoing clinical developments and strengthening its position in the cell therapy industry.
Chimeric Therapeutics Limited has requested a voluntary suspension of its securities from the Australian Securities Exchange (ASX) pending an announcement related to a capital raising. The suspension follows a previous trading halt due to the limited availability of investors during the reporting season. This move is anticipated to impact the company’s financial strategy and market operations as it seeks non-dilutionary funding.
Chimeric Therapeutics Limited reported a significant increase in losses for the half-year ended December 31, 2024, with a 216.9% rise in losses attributable to owners, totaling $2,857,887. Despite the financial setback, the company’s net tangible assets per ordinary security improved from (1.09) cents to (0.35) cents, indicating a potential stabilization in asset valuation. No dividends were declared for the current or previous financial periods, and the company’s financial statements were reviewed with a material uncertainty regarding its going concern status.
Chimeric Therapeutics has secured approximately A$4.0 million in non-dilutionary funding from a US-based philanthropic family office to advance its CHM CDH17 CAR-T cell therapy. This funding supports the ongoing Phase 1/2 clinical trial aimed at determining the recommended Phase 2 dose and evaluating the safety and response rate in patients with advanced gastrointestinal cancers. The investment underscores the potential of CHM CDH17, a novel therapy targeting CDH17, which is linked to poor prognosis in common gastrointestinal cancers.
Chimeric Therapeutics Limited has announced the quotation of 20 million ordinary fully paid securities on the Australian Securities Exchange (ASX), which forms part of a previously announced transaction. This move is expected to broaden the company’s capital base, potentially enhancing its financial capacity to advance its cancer treatment therapies, thereby potentially impacting its market position and stakeholder interests positively.
Chimeric Therapeutics has announced the issuance of up to 124,888,889 new fully paid ordinary shares to Lind Global Fund II, LP, as part of a share subscription agreement. This move aims to facilitate funding previously advanced by Lind, potentially enhancing the company’s financial stability and market operations.
Chimeric Therapeutics announced that the University of Chicago Medicine has joined its Phase 1/2 clinical trial for CHM CDH17, a pioneering anti-CDH17 CAR-T cell therapy. This trial targets advanced colorectal, gastric, and intestinal neuroendocrine cancers, with the goal of determining the Phase 2 dose and evaluating safety and response rates. The inclusion of a prestigious institution like UChicago Medicine highlights the potential impact of this therapy on the treatment of gastrointestinal tumors.